Regeneron Pharmaceuticals Inc (REGN) FY2025Q2 Earning Prediction

08/01 04:00:00

Pre-Market

Regeneron Pharmaceuticals Inc (REGN) is set to release its FY2025Q2 earnings performance on 08/01 04:00:00 in Pre-Market trading. Consensus forecasts predict a revenue of 3.28B and an earnings per share (EPS) of 7.44 for the FY2025Q2. With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!

Estimate

Actual

Surprise

RevenueBEAT

3.28B

3.68B

+12.02%

EPSBEAT

7.44

12.89

+73.25%

AI Earnings Prediction

Prediction for FY2025Q2

Earnings Date: Aug 1, 2025

The earnings forecast predicts a Beat, driven by Dupixent's growth and new approvals countering EYLEA's decline.

Beat

Last 0 quarters:

4 beats1 misses

Scenario Analysis

The AI analyzes the probability of each scenario occurring and identifies the triggering conditions.

Scenario

Prob.

Stock Reaction

Trigger Condition

Strong Beat

20%

+8–12%

EYLEA decline <5% + Dupixent sales >$3.1B.

Beat

45%

+3–7%

Dupixent sales inline ($2.9B–$3.0B), Lynozyfic contribution.

Neutral

20%

Flat

EYLEA sales miss >10%, collaboration revenue flat.

Miss

10%

-4–6%

Dupixent growth <5% QoQ + margin contraction.

Strong Miss

-10–15%

EYLEA collapse (-20% YoY) + pipeline delays.

Unlock Free Scenario Probability

Key Indicators Forecast

The AI provides itemized forecasts for key indicators, potentially including revenue, EPS, gross margin, and free cash flow.

Revenue

EPS

Currency:

No data

Actual

Estimate

Metric

Prediction

Justification

Revenue

Beat

Dupixent’s new indications + Lynozyfic launch offset EYLEA declines.

EPS

Beat

Higher Dupixent sales (+collab revenue) and cost controls mitigate margin pressure.

Unlock Free Key Indicators Forecast

Prediction Logic & Rational

Justification:
While EYLEA franchise weakness persists, Dupixent's expanded approvals and superior clinical trial results create upside potential. Key Fact Data points include:

Dupixent Growth Drivers:

FDA approval for bullous pemphigoid (June 2025) and positive Phase 4 EVEREST trial results (vs. Xolair).
Strong ASCO/ATS conference data reinforces demand across indications.

Pipeline Offsets:

Accelerated FDA approval for Lynozyfic (relapsed multiple myeloma) and Libtayo DFS improvements (Phase 3 C-POST).

Collaboration Revenue Stability:

Dupixent volume growth likely offsets Sanofi partnership risks from itepekimab’s COPD failure.

Market Expectations:

Stock underperformed S&P 500 (- 5.3% vs. + 13.7%), suggesting low expectations priced in.

Prediction Logic & Rational

Tactical Strategy Recommendations

Stock: Long REGN ahead of earnings. Upside to $600–620 on Beat.
Options:
- Buy August $570/$600 call spread.
- Hedge with September $520 puts (EYLEA downside risk).
Catalysts to Watch:
- Q2 Dupixent sales growth rate vs. Q1 (+14% YoY).
- EYLEA HD adoption post-Q1 inventory write-offs.

Tactical Strategy Recommendations

Earnings Surprise Analysis

The chart displays the extent of earnings surprises and corresponding stock price movements for each earnings event.

Revenue

EPS

REGN Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Neutral12-3

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Neutral12-2

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference 2025 Transcript

Neutral11-17

Regeneron Pharmaceuticals, Inc. (REGN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Neutral11-17

REGN Slides

Regeneron Q2 2025 slides: revenue rebounds to $3.68B after Q1 miss

2025-08-01

Regeneron Q3 2025 slides: Dupixent drives growth as pipeline expands

2025-10-28

REGN Report

REGENERON PHARMACEUTICALS, INC. 10-Q

10-Q

2025-08-01

REGENERON PHARMACEUTICALS, INC. 10-K

10-K

2025-02-05

REGENERON PHARMACEUTICALS, INC. 10-Q

10-Q

2024-10-31

REGENERON PHARMACEUTICALS, INC. 10-Q

10-Q

2024-08-01

Frequently Asked Questions

What is the Regeneron Pharmaceuticals Inc FY2025Q2 Earnings Release Date and Time?

Regeneron Pharmaceuticals Inc (REGN) is scheduled to release its FY2025Q2 earnings report onAug 1, 2025, Pre-Market(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.

What Are the Consensus Forecasts for Regeneron Pharmaceuticals Inc FY2025Q2 Revenue and EPS?

Analysts' consensus predicts 3.28B in revenue and an EPS of 7.44 for Regeneron Pharmaceuticals Inc's FY2025Q2.

What Does Intellectia's AI Predict for Regeneron Pharmaceuticals Inc FY2025Q2 Earnings?

Intellectia's exclusive AI algorithms forecast a Beat forRegeneron Pharmaceuticals Inc's FY2025Q2 earnings, with a prediction date of Aug 1, 2025. Regeneron Pharmaceuticals Inc The earnings forecast predicts a Beat, driven by Dupixent's growth and new approvals countering EYLEA's decline.

How Can I Use This Earnings Prediction to Trade REGN Stock?

Leverage Intellectia's AI forecast to position trades ahead of theAug 1, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.

How Accurate Is Intellectia's AI for Earnings Predictions Like Regeneron Pharmaceuticals Inc FY2025Q2?

Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.

How does AI Earnings Prediction generate its forecasts?

AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!

When are the predictions available, and how often are they updated?

Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.

Can I use AI Earnings Prediction for all types of stocks?

Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2024-2025 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!